Abstract
Purpose
Pollakiuria is defined as a change in the pattern of daily urination. Students have mentioned wetting their pants at school as the third tragic event after the death of a parent or going blind. In this study, the effect of adding Montelukast to oxybutynin on the improvement of urinary symptoms of patients with pollakiuria was studied.
Materials and methods
This study was a pilot clinical trial in which children with pollakiuria aged 3–18 years old were included. These children were randomly divided into two groups of intervention (Montelukast plus oxybutynin) and the control group (only oxybutynin). At the beginning and the end of the study (after 14 days), mothers were asked about the frequency of daily urination. Finally, the gathered data were compared between two groups.
Results
In the present study, 64 patients were examined in two intervention and control groups (32 in each group). The results revealed that although significant changes were observed in both groups before and after intervention, the average changes in the intervention group were significantly higher (p = 0.014).
Conclusion
The results of this study showed that adding montelukast to oxybutynin has a significant decrease in frequency of daily urination in patients with pollakiuria, although further studies are recommended in this area.
Similar content being viewed by others
Availability of data and materials
The datasets used and analyzed during the current study are available to be collected from the corresponding author on reasonable request.
References
Bergmann M, Corigliano T, Ataia I, Renella R, Simonetti GD, Bianchetti MG, von Vigier RO (2009) Childhood extraordinary daytime urinary frequency-a case series and a systematic literature review. Pediatr Nephrol 24(4):789–795. https://doi.org/10.1007/s00467-008-1082-9
Watemberg N, Shalev H (1994) Daytime urinary frequency in children. Clin Pediatr 33(1):50–53
Sureshkumar P, Jones M, Cumming R, Craig J (2009) A population based study of 2856 school-age children with urinary incontinence. J Urol 181(2):808–815. https://doi.org/10.1016/j.juro.2008.10.044. (Discussion 815-806)
Kajiwara M, Inoue K, Kato M, Usui A, Kurihara M, Usui T (2006) Nocturnal enuresis and overactive bladder in children: an epidemiological study. Int J Urol 13(1):36–41. https://doi.org/10.1111/j.1442-2042.2006.01217.x
Hellström AL, Hanson E, Hansson S, Hjälmås K, Jodal U (1990) Micturition habits and incontinence in 7-year-old Swedish school entrants. Eur J Pediatr 149(6):434–437. https://doi.org/10.1007/BF02009667
Hägglöf B, Andrén O, Bergström E, Marklund L, Wendelius M (1998) Self-esteem in children with nocturnal enuresis and urinary incontinence: improvement of self-esteem after treatment. Eur Urol 33(Suppl 3):16–19. https://doi.org/10.1159/000052236
Ollendick TH, King NJ, Frary RB (1989) Fears in children and adolescents: reliability and generalizability across gender, age and nationality. Behav Res Ther 27(1):19–26. https://doi.org/10.1016/0005-7967(89)90115-0
Bower WF (2008) Self-reported effect of childhood incontinence on quality of life. J Wound, Ostomy, Continence Nurs 35(6):617–621. https://doi.org/10.1097/01.won.0000341476.71685.78
Bower WF, Moore KH, Shepherd RB, Adams RD (1996) The epidemiology of childhood enuresis in Australia. Br J Urol 78(4):602–606. https://doi.org/10.1046/j.1464-410x.1996.13618.x
Bauer SB, Retik AB, Colodny AH, Hallett M, Khoshbin S, Dyro FM (1980) The unstable bladder in childhood. Urol Clinics N Am 7(2):321–336
Fitzgerald MP, Thom DH, Wassel-Fyr C, Subak L, Brubaker L, Van Den Eeden SK, Brown JS (2006) Childhood urinary symptoms predict adult overactive bladder symptoms. J Urol 175(3 Pt 1):989–993. https://doi.org/10.1016/s0022-5347(05)00416-7
Kuh D, Cardozo L, Hardy R (1999) Urinary incontinence in middle aged women: childhood enuresis and other lifetime risk factors in a British prospective cohort. J Epidemiol Community Health 53(8):453–458. https://doi.org/10.1136/jech.53.8.453
Tsai ML, Lin HC, Yen CH, Ku JT, Sung SY, Chang H (2022) Increased Risk of Tourette syndrome with Leukotriene modifier use in children with allergic diseases and asthma: a nationwide population-based study. Children. https://doi.org/10.3390/children9111607
Heydari S, Khoshmohabat H, Akerdi AT, Ahmadpour F, Paydar S (2022) Evaluating the effect of montelukast tablets on respiratory complications in patients following blunt chest wall trauma: a double-blind, randomized clinical trial. Chin J Traumatol. https://doi.org/10.1016/j.cjtee.2022.10.002
Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, Holgate ST, Davies DE (2005) Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 201(6):937–947. https://doi.org/10.1084/jem.20041901
Fraenkel DJ, Bardin PG, Sanderson G, Lampe F, Johnston SL, Holgate ST (1995) Lower airways inflammation during rhinovirus colds in normal and in asthmatic subjects. Am J Respir Crit Care Med 151(3 Pt 1):879–886. https://doi.org/10.1164/ajrccm/151.3_Pt_1.879
van Adelsberg J, Philip G, Pedinoff AJ, Meltzer EO, Ratner PH, Menten J, Reiss TF (2003) Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy 58(12):1268–1276. https://doi.org/10.1046/j.1398-9995.2003.00261.x
Virchow JC, Bachert C (2006) Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med 100(11):1952–1959. https://doi.org/10.1016/j.rmed.2006.02.026
WajihUllah M, Lakhani S, Sham S, Rehman A, Siddiq W, Siddiqui T (2018) Painful bladder syndrome/interstitial cystitis successful treatment with montelukast: a case report and literature review. Cureus. 10(6):e2876. https://doi.org/10.7759/cureus.2876
Schulz KF, Altman DG, Moher D, The CG (2010) CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Medicine 8(1):18. https://doi.org/10.1186/1741-7015-8-18
Kliegman RM, Toth H, Bordini BJ, Basel D (2022) nelson pediatric symptom-based diagnosis e-book, 21st edn. Elsevier Health Sciences, New York
Taherahmadi H, Yousefichaijan P, Rezagholizamenjany M, Kahbazi M, Nazari T (2019) Investigating the effect of montelukast on the pyelonephritis symptoms in children. Nephro-Urol Monthly 11(4):e96626. https://doi.org/10.5812/numonthly.96626
Aigner L, Pietrantonio F, Bessa de Sousa DM, Michael J, Schuster D, Reitsamer HA, Zerbe H, Studnicka M (2020) The leukotriene receptor antagonist montelukast as a potential COVID-19 therapeutic. Front Mol Biosci. 7:610132. https://doi.org/10.3389/fmolb.2020.610132
Anderson R, Theron AJ, Gravett CM, Steel HC, Tintinger GR, Feldman C (2009) Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism. Br J Pharmacol 156(1):105–115. https://doi.org/10.1111/j.1476-5381.2008.00012.x
Marques CF, Marques MM, Justino GC (2022) The mechanisms underlying montelukast’s neuropsychiatric effects—new insights from a combined metabolic and multiomics approach. Life Sci. 310:121056. https://doi.org/10.1016/j.lfs.2022.121056
Dülger EÇ, Şener G, Çetinel Ş, Ercan F, Çanillioğlu YE (2018) Protective effects of Montelukast against stress-induced degeneration of the urinary bladder. Clin Exp Health Sci 8(3):211–216. https://doi.org/10.5152/clinexphealthsci.2017.691
Traut JL, Macdonald ES, Spangler ML, Saxena S (2011) Montelukast for symptom control of interstitial cystitis. Ann Pharmacother 45(9):e49. https://doi.org/10.1345/aph.1Q130
Sterrett S, Morton J, Perry D, Donovan J (2006) Eosinophilic cystitis: Successful long-term treatment with montelukast sodium. Urology 67(2):423.e419-423.e421. https://doi.org/10.1016/j.urology.2005.08.059
Dobrek L, Skowron B, Baranowska A, Thor PJ (2015) The influence of montelukast on the autonomic nervous system activity in rats with cyclophosphamide-induced hemorrhagic cystitis. Curr Issues Pharm Medi Sci 28(3):170–175. https://doi.org/10.1515/cipms-2015-0066
Bouchelouche K, Nordling J, Hald T, Bouchelouche P (2001) Treatment of interstitial cystitis with montelukast, a leukotriene D(4) receptor antagonist. Urology 57(6 Suppl 1):118. https://doi.org/10.1016/s0090-4295(01)01066-4
Bouchelouche K, Andersen L, Nordling J, Horn T, Bouchelouche P (2003) The cysteinyl-leukotriene D4 induces cytosolic Ca2+ elevation and contraction of the human detrusor muscle. J Urol 170(2 Pt 1):638–644. https://doi.org/10.1097/01.ju.0000076390.30043.ff
Acknowledgements
The authors would like to thanks Arak University of Medical Sciences for their scientific and financial support.
Funding
This study was funded by Vice-chancellor for Research of Arak University of Medical Sciences.
Author information
Authors and Affiliations
Contributions
Study conception and design: AAS, HB, FD, PY, and AAH. Data collection, statistical expertise, analysis and interpretation of data: AAS, HB and AAH. Manuscript preparation, supervision, administrative support and critical revision of the paper: AAS, HB, FD, PY and AAH. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
All authors declared that they have no conflict of interest.
Ethical approval and consent to participate
All stages of research were conducted following the Declaration of Helsinki and the Ethical Statements of the Ethics Committee of Arak University of Medical Sciences. This study was approved by the Ethics Committee of Arak University of Medical Sciences (Ethical code: IR.ARAKMU.REC.1400.054). The parents or legal guardians of subjects provided written informed consent on their behalf. The children were also asked verbally if they were willing to participate in the study.
Consent for publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Arjmand Shabestari, A., Bakhtiari, H., Dorreh, F. et al. The effect of adding Montelukast to oxybutynin on daily urination in children with pollakiuria: a randomized clinical trial. Int Urol Nephrol 55, 2139–2144 (2023). https://doi.org/10.1007/s11255-023-03673-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-023-03673-3